NCT00476268View on ClinicalTrials.gov

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

PHASE3CompletedINTERVENTIONAL

Enrollment

824

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Asthma

Interventions

DRUG

beclomethasone/formoterol (100/6µg) pMDI

Two puffs b.i.d

DRUG

Beclometasone dipropionate 250 µg/unit dose pMDI

2 inhalations bid

DRUG

Formoterol powder 12 µg/unit dose

2 inhalations bid

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT00476268 - Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma | Biotech Hunter | Biotech Hunter